tocilizumab + disease-modifying antirheumatic drugs

A combination drug regimen consisting of **tocilizumab**, a humanized monoclonal antibody targeting the interleukin-6 receptor, plus one or more **disease-modifying antirheumatic drugs (DMARDs)**, such as methotrexate, leflunomide, or sulfasalazine. This combination is used primarily for patients with **rheumatoid arthritis** and other autoimmune or inflammatory diseases who have had an inadequate response to DMARDs alone. Tocilizumab inhibits the binding of interleukin-6 (IL-6) to its receptor, thus suppressing IL-6–mediated pro-inflammatory signaling that plays a key role in the pathogenesis of rheumatoid arthritis and related disorders. Use of tocilizumab with DMARDs generally provides superior disease control compared to DMARD monotherapy, and common clinical endpoints include improvements in the American College of Rheumatology (ACR) response and Disease Activity Score (DAS28) metrics. Combination therapy has a comparable safety profile to monotherapy, with increased attention to the risk of infections and changes in laboratory values such as lipid and liver enzyme levels[1][3][5][7].

Brand names

ActemraRoActemra

Other names

tocilizumab plus standard DMARDstocilizumab + methotrexatetocilizumab + csDMARDstocilizumab combination therapy